These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26137891)

  • 1. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment.
    Borekci S; Atahan E; Demir Yilmaz D; Mazıcan N; Duman B; Ozguler Y; Musellim B; Hamuryudan V; Ongen G
    Respiration; 2015; 90(3):191-8. PubMed ID: 26137891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
    Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.
    Ozguler Y; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Borekci S; Atahan E; Ongen G; Hamuryudan V
    Rheumatol Int; 2016 Dec; 36(12):1719-1725. PubMed ID: 27699578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.
    Kisacik B; Pamuk ON; Onat AM; Erer SB; Hatemi G; Ozguler Y; Pehlivan Y; Kilic L; Ertenli I; Can M; Direskeneli H; Keser G; Oksel F; Dalkilic E; Yilmaz S; Pay S; Balkarli A; Cobankara V; Cetin GY; Sayarlioglu M; Cefle A; Yazici A; Avci AB; Terzioglu E; Ozbek S; Akar S; Gul A
    J Rheumatol; 2016 Mar; 43(3):524-9. PubMed ID: 26773107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.
    Ai JW; Zhang S; Ruan QL; Yu YQ; Zhang BY; Liu QH; Zhang WH
    J Rheumatol; 2015 Dec; 42(12):2229-37. PubMed ID: 26472414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area.
    Kim HW; Park JK; Yang JA; Yoon YI; Lee EY; Song YW; Kim HR; Lee EB
    Clin Rheumatol; 2014 Sep; 33(9):1307-12. PubMed ID: 24057090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.
    Ke WM; Chen LS; Parng IM; Chen WW; On AW
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1590-5. PubMed ID: 24200274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for tuberculosis in patients receiving tumour necrosis factor-α blockers: what do we really know?
    Botha PR; Koegelenberg CF
    Respiration; 2015; 90(3):185-6. PubMed ID: 26278409
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents.
    Ergun T; Seckin D; Baskan Bulbul E; Onsun N; Ozgen Z; Unalan P; Alpsoy E; Karakurt S
    Int J Dermatol; 2015; 54(5):594-9. PubMed ID: 25753908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.
    Pamuk ÖN; Kalyoncu U; Aksu K; Omma A; Pehlivan Y; Çağatay Y; Küçükşahin O; Dönmez S; Çetin GY; Mercan R; Bayındır Ö; Çefle A; Yıldız F; Balkarlı A; Kılıç L; Çakır N; Kısacık B; Öksüz MF; Çobankara V; Onat AM; Sayarlıoğlu M; Öztürk MA; Pamuk GE; Akkoç N
    Rheumatol Int; 2016 Jul; 36(7):945-53. PubMed ID: 27221456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature.
    Gazel Ü; Kocakaya D; Hicret Topçu İ; Ömer Karataş H; Karabacak M; Atagündüz MP; İnanç GN; Alibaz Öner F; Direskeneli RH
    Turk J Med Sci; 2021 Aug; 51(4):1689-1694. PubMed ID: 33535732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk.
    Cagatay T; Bingol Z; Kıyan E; Yegin Z; Okumus G; Arseven O; Erkan F; Gulbaran Z; Erelel M; Ece T; Cagatay P; Kılıçaslan Z
    Clin Respir J; 2018 Apr; 12(4):1668-1675. PubMed ID: 29028148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden.
    Tam LS; Leung CC; Ying SK; Lee GK; Yim CW; Leung YY; Kun EW; Wong KK; Li EK
    Clin Exp Rheumatol; 2010; 28(5):679-85. PubMed ID: 20822708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
    Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
    Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of anti-tumor necrosis factor therapy in South African rheumatoid arthritis patients.
    Pettipher C; Rudolph R; Musenge E; Tikly M
    Int J Rheum Dis; 2016 Jun; 19(6):594-9. PubMed ID: 24517208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy.
    Yoo IK; Choung RS; Hyun JJ; Kim SY; Jung SW; Koo JS; Lee SW; Choi JH; Kim H; Lee HS; Keum B; Kim ES; Jeen YT
    Yonsei Med J; 2014 Mar; 55(2):442-8. PubMed ID: 24532516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.